Misonix Demonstrates neXus, the First Fully Integrated, Smart Technology Ultrasonic Surgical Aspirator Platform at NASS 2018...
September 27 2018 - 4:30PM
Misonix, Inc. (NASDAQ: MSON) (“Misonix” or “the Company”), a
provider of minimally invasive therapeutic ultrasonic medical
devices that enhance clinical outcomes, demonstrated for the first
time publicly its next generation platform technology, neXus. neXus
combines all the features of Misonix’s existing solutions,
including BoneScalpel, SonicOne and Sonastar, into one fully
integrated platform. The new platform is targeted to be launched in
the first half of 2019 after FDA 510(k) clearance. The neXus
platform is driven by a new proprietary digital algorithm that
results in more power, efficiency and control. The device also
incorporates Smart Technology that allows for easier setup and use.
Stavros Vizirgianakis, President and Chief
Executive Officer of Misonix, commented, “The unveiling of
neXus is a significant milestone for Misonix, one we are confident
will help us to further our market penetration and reach, both
across new as well as existing markets. As we continue to
strategically invest in our product development and accelerate our
efforts to become the standard of care in operating rooms and
hospital outpatient departments, we are confident that our
therapeutic ultrasonic medical expertise and leadership will be
significantly strengthened by the addition of a new, highly
complementary solution such as neXus.”
The 2018 North American Spine Society conference
presented the perfect platform for Misonix to demonstrate neXus.
Dr. Thomas Doers, Director Surgical Spine Services at Aurora
Healthcare in the greater Milwaukee area, used neXus during a live
surgical lab to demonstrate some of the new features. Dr. Doers,
commented, “Physicians will definitely be able to tell neXus has
higher power, which will translate to more efficient bone removal.
I especially like the ability to be able to resect both bone and
soft tissue in one product and envision the ability to expand the
utilization of ultrasonic surgical applications due to neXus’
increased features.”
About Misonix,
Inc.Misonix, Inc. (NASDAQ: MSON) designs,
manufactures and markets ultrasonic medical devices for the precise
removal of hard and soft tissue, including bone removal, wound
debridement and ultrasonic aspiration. Misonix is focused
on leveraging its proprietary ultrasonic technology to become the
standard of care in operating rooms and clinics around the
world. Misonix's proprietary ultrasonic medical devices
are used in a growing number of medical procedures, including spine
surgery, neurosurgery, orthopedic surgery, cosmetic surgery,
laparoscopic surgery, and other surgical and medical applications.
At Misonix, Better Matters to us. That is why throughout the
Company’s history, Misonix has maintained its commitment
to medical technology innovation and the development of ultrasonic
surgical products that radically improve patient outcomes.
Additional information is available on the Company's web site
at www.misonix.com.
Safe Harbor StatementWith the
exception of historical information contained in this press
release, content herein may contain “forward looking statements”
that are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based on management’s current expectations and are subject to
uncertainty and changes in circumstances. Investors are cautioned
that forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from the
statements made. These factors include general economic conditions,
delays and risks associated with the performance of contracts,
risks associated with international sales and currency
fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying
levels of statistical relevancy, risks involved in introducing and
marketing new products, potential acquisitions, consumer and
industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing
of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated
510(k) filings, the ability to achieve and maintain profitability
in the Company’s business lines, the impact of the pending
investigation by the Department of
Justice and Securities Exchange Commission, and other
factors discussed in the Company’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2018, subsequent Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking
statements.
Contact: Joe DwyerChief
Financial OfficerMisonix, Inc.631-694-9555
Joseph Jaffoni, Norberto Aja, Jennifer NeumanJCIR212-835-8500 or
mson@jcir.com
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Apr 2023 to Apr 2024